Eubel Brady & Suttman Asset Management Inc. Sells 200 Shares of Merck & Co., Inc. $MRK

Eubel Brady & Suttman Asset Management Inc. lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 3.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,866 shares of the company’s stock after selling 200 shares during the quarter. Eubel Brady & Suttman Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $464,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.6% in the first quarter. Vanguard Group Inc. now owns 252,513,381 shares of the company’s stock valued at $22,665,601,000 after purchasing an additional 1,417,274 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 1.1% during the first quarter. Wellington Management Group LLP now owns 81,669,651 shares of the company’s stock worth $7,330,668,000 after acquiring an additional 927,621 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after acquiring an additional 29,104,112 shares during the period. Amundi lifted its holdings in Merck & Co., Inc. by 37.1% during the first quarter. Amundi now owns 13,077,716 shares of the company’s stock worth $1,130,397,000 after acquiring an additional 3,542,036 shares during the period. Finally, Nuveen LLC bought a new stake in Merck & Co., Inc. during the first quarter worth $991,553,000. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on MRK shares. Citigroup started coverage on Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Wells Fargo & Company dropped their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Morgan Stanley dropped their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $87.13 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The business has a fifty day simple moving average of $84.55 and a two-hundred day simple moving average of $81.67. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $105.11. The company has a market capitalization of $217.62 billion, a P/E ratio of 13.42, a P/E/G ratio of 0.97 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. On average, analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.